Clinical trial · Interventional
Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block
Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Patient Undergoing Breast Cancer Surgery :A Comparative Study
NCT03063073CI-TRIAL-00103157pec'scompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Pecs block (pectoral nerves block) is an easy and reliable superficial block inspired by the infraclavicular block approach and the intercostal abdominis plane blocks . Many additives were used in combination with local anesthetics in Pecs block to prolong the postoperative analgesia (fentanyl, dexmedetomidine).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Female | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacaine Injection [Marcaine] | Drug | — | UNRESOLVED |
| Dexmedetomidine Injection [Precedex] | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Group I (Bupivacaine group)
- description
- ultrasound guided modified Pec's block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle
- interventionNames
- Drug: Bupivacaine Injection [Marcaine]
- type
- ACTIVE_COMPARATOR
- label
- Dexmedetomidine Injection [Precedex]
- description
- ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection \[Precedex\] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.
- interventionNames
- Drug: Dexmedetomidine Injection [Precedex]
- Drug: Bupivacaine Injection [Marcaine]
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * ASA I - II patients * weight 50- 100 kg * age 18-60 years Exclusion Criteria: * History of bleeding diathesis * Relevant drug allergy * Opioid dependence * Sepsis * Those with psychiatric illnesses that would interfere with perception and assessment of pain will be excluded from the study
References
Publications (0)
Data not yet available
No reference posted for this study.